MLI Certified

On-Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
GVHD-E3 | ECHO Program: Sclerotic Chronic GVHD
The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care.     The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients.
Episode 2 of 4 of the series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes
What You MUST Know as More Lymphoma Patients Are on the Road to CAR-T, episode 2 of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. Through interactive discussion among cellular therapy experts and a community-based oncologist, this activity provides practical information regarding management of acute, delayed, and late toxicities of CAR-T therapy and what your patients and their caregivers need to know before, during, and after treatment. Videos, animations, and key learning points address clinical challenges with interprofessional perspectives to foster meaningful change.
Episode 4 of 4 of the series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes
Opening the CAR(T) Door to Get Patient to Therapy, episode 4 of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes patient video clips and numerous downloadable resources including a directory of CAR-T treatment centers organized by state. This activity focuses on managing logistics associated with CAR-T therapy, including common misperceptions, the numerous services offered by treating centers, and how to overcome roadblocks for your patients.
Upstream and Downstream Targeting of the Complement Pathway to Manage PNH: Current and Emerging Inhibitors
In this activity, an expert in hematology-oncology provides an overview of paroxysmal nocturnal hemoglobinuria (PNH) and discusses current and emerging treatment options for managing PNH
Taking it From the Top: Targeting a New Approach to Control Severe Asthma
In this activity, experts in asthma detail the pathophysiology of severe asthma, with a discussion of the underlying mechanisms behind both type 2 and non–type 2 asthma, and novel and emerging therapies for its treatment.
Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes
In this activity, an expert in hypereosinophilic syndrome discusses the burden, symptoms, and differential diagnosis of the disease, as well as the latest data on treatment.
Selective Inhibition of Oncogenic Transcription and Other Novel Approaches in the Treatment of Small Cell Lung Cancer: An Illustrative Guide to Navigating the Evolving Treatment Landscape and Integrating Latest Treatment Modalities Into Clinical Care
In this activity, an expert in small cell lung cancer provides an overview of the features and challenges associated with the condition, as well as the current treatment landscape.
Episode 1 of 3 - What You MUST Know About the Emerging Standard of Care for 1L Treatment of CLL and SLL
The treatment landscape in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has shifted with the advent of novel targeted agents that are more tolerable than traditional chemoimmunotherapy. However, keeping up with the latest clinical evidence and updates to the clinical guidelines on these agents can be challenging for busy clinicians and their care teams. In this first episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, sit in on a conversation with our expert faculty as they discuss the new standard of care for CLL and SLL and how to apply this care transition to your patients and clinic.
Mastering MRD for Prognosis and Treatment in ALL
Acute lymphoblastic leukemia (ALL) is the first hematologic neoplasm for which assessment of early response to therapy using measurable residual disease (MRD) has proven to be a fundamental tool for guiding therapy. It should be a key component in individualizing care to improve outcomes for patients. But MRD is a time point-dependent variable, with different time points signifying different prognosis for relapse. And MRD testing methods are variable across clinical practices, and it can be challenging to select the appropriate combination and sequence of therapy. Consequently, not all patients are provided with uniform care. During Mastering MRD for Prognosis and Treatment in ALL, experts will discuss conducting MRD testing for patients with ALL according to the guideline-recommended schedule; evaluating the specimens needed for, and the pros and cons of, various methods for assessing MRD; predicting the risk of relapse based on MRD test results; and individualizing treatment based on MRD status to ensure patients at higher risk of relapse receive appropriate risk-adapted therapy. This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part II: Treating Acquired Resistance and Evaluating Next-generation Therapies
The evolution of the non-small cell lung cancer (NSCLC) treatment landscape and the discovery of predictive biomarkers that can be targeted by novel therapies or combinations is facilitating more individualized treatment. However, drug resistance plays a major role in therapeutic failure and clinicians must stay alert to the current and emerging treatment options to provide optimal care. Are you ready to test your skills amongst your colleagues? Join us for Part 2 of this question and answer based educational activity Treating Acquired Resistance and Evaluating Next-generation Therapies where our oncology experts will: Discuss treatment selection for patients with acquired resistance to targeted therapy Present the latest clinical evidence on new and emerging targeted therapies Provide strategies to promote patient engagement in their care
Potential Benefits of Incretins Beyond Glycemic Control in T2D
Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs.  What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes. This taped satellite symposium was derived from the 58th EASD Annual Meeting on September 19, 2022.
Seeing Eye to Eye: Improving Outcomes Among Rural Spanish-Speaking Latinx Patients with Diabetic Retinopathy or Diabetic Macular Edema
In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas.
The Evolving Role of Oxybate Agents in the Management of Narcolepsy: A Visual Exploration of Individualized Care
In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care.
Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancer: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy
Esophageal cancer has a poor prognosis with 5-year survival rates below 35% in the non-metastatic setting. Despite the use of trimodality approaches with chemotherapy, radiation, and surgery, survival benefits remain suboptimal. Promisingly, recent phase 3 evidence suggests that adjuvant immunotherapy can significantly improve disease-free survival in patients with esophageal or gastroesophageal junction (GEJ) cancer. Moreover, a number of other trials are underway studying approaches that harness the patient’s own immune system with immunotherapy in different settings of locally advanced and earlier stage, indicating the expanding role of immunotherapy in the therapeutic management of esophageal or GEJ cancer. Preparing for new treatment strategies that can improve patient outcomes requires the cancer care team of radiation, medical, and surgical oncologists to work in a concerted multidisciplinary approach. This activity will provide a comprehensive and practically-oriented, multidisciplinary overview on the expanding role of immunotherapy in esophageal and GEJ cancer. Radiation and medical oncology experts will offer their insights to optimize the integration and use of immunotherapies in the multimodal management of esophageal and GEJ cancer.
CLL-SLL/MTT Episode 2 of 3 - Moving Towards Fixed-Duration Therapy in CLL and SLL
The emergence of fixed-duration therapy, which combines two or more drugs within a set timeframe, has shown promise for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, it leads to many clinical questions regarding establishing an optimal combinational therapy and sequence to best fit the needs of the patient. Join us for the second episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement as our experts and special guests discuss the implications of the new data in fixed-duration therapy, as well as strategies to promote inclusive clinical trial participation.
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment
In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will: Review guideline recommendations for biomarker testing and treatment selection Present clinical evidence for the use of current and emerging targeted therapies Discuss health disparities in biomarker testing
Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm
Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm
Episode 1 of 3: What You Need to Know About New Targeted Therapies for AD
In episode 1 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss what practicing clinicians need to know about newly approved oral JAK inhibitors. This activity focuses on the mechanism of action of novel targeted agents, their key safety and efficacy data, and their role in the treatment paradigm for atopic dermatitis.
Breakthroughs in Spinal Muscular Atrophy: Managing the Life-Changing Impact of Gene Replacement Therapy
In this activity, a neurologist discusses the life-changing impact of gene replacement therapy in spinal muscular atrophy.
Episode 3 of 3: Practical Approaches to Enhance Care for Individuals with Atopic Dermatitis: A Med Table Talk™: Targeted Therapy in Atopic Dermatitis Series
In episode 3 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss practical approaches to improve care for patients with moderate-to-severe disease. Topics include best practices for vaccination, considerations for patients in special populations, and advocating for access to novel therapies.
A New Era of Migraine Management: Recent Updates on Recognition, Acute Treatment and Prevention for Emergency Physicians
In this activity, an expert in emergency medicine discusses the diagnosis and management of patients with migraine in the emergency department setting.
Episode 1 of 4 - The Evolution of Biomarker Testing: Revolutionizing Treatment of NSCLC
Biomarker testing can have a significant impact on the treatment plan of patients with non-small cell lung cancer (NSCLC).  In this first episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care, expert faculty apply the latest clinical guidelines and give practical tips on breaking down barriers for oncology teams to successfully implement biomarker testing for NSCLC patients, including those in underserved populations.
Episode 1 of 2: Talk to Me About Dual Agonists
For prescribers and non-prescribers alike, therapeutic inertia can be a big challenge when trying to optimize therapy to control patients’ glucose levels and improve their overall health. Such obstacles can be even more difficult when trying to switch treatment regimens. Novel therapies can be miracles, but only if patients can actually get them. In Talk to Me About Dual Agonists, episode 1 of the Med Table TalkTM series, certified diabetes care and education specialists address therapeutic inertia and the need to treat the whole person, rather than just A1C. They then explain the mechanisms of action, efficacy and safety, and precautions for using a unimolecular dual agonist and strategies for helping patients gain access.
Refractory Ascites and Esophageal Variceal Hemorrhage: Practical Guidance to Improve Patient Outcomes
In this activity, an expert on refractory ascites and esophageal variceal hemorrhage (EVH) discusses evidence-based strategies to improve patient outcomes.